What cancer drug companies came out ahead at this weekend's ASCO conference and a closer look at Biogen's recent disappointment.

With massive, multi-billion dollar valuations, unicorn start-ups Uber and Lyft are locked in an intense, sometimes controversial, race to become the ride of choice for users all over the world. We look at the stories behind each company and how their expansion plans are pushing them into complementary industries like delivery and driverless cars, often with the help of industry incumbents. 

Understanding the ins and outs of individual retirement accounts can give your retirement savings a jump-start. 

We discuss the P/E ratio and what it implies. Premium analyst Simon Erickson joins the show to explain how some Fools’ mentality towards the metric is different than most investors.

Tune in to hear why Petrobras and Vale, two Brazilian energy companies that seem to be bottoming out, might not be worth the potential upside amidst seemingly endless corruption scandals.

Also, our analysts look at the most important points from OPEC’s meeting this week, and why 2015 clocked the lowest level of oil finds we’ve seen in six decades.